Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study. (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.2147/ndt.s385631
PubMed Identifier: 36349345
Publication URI: http://europepmc.org/abstract/MED/36349345
Type: Journal Article/Review
Volume: 18
Parent Publication: Neuropsychiatric disease and treatment
ISSN: 1176-6328